Head to head · SEC data as of September 11, 2026
Merck
48
Quality score · out of 100
Bristol Myers Squibb
77
Quality score · out of 100
Bristol Myers Squibb comes in ahead: a quality score of 77 versus 48 for Merck. Bristol Myers Squibb wins on net margin (18.9% vs 4.8%), ROE (41.6% vs 7.6%) and earnings growth (8.7% vs -13.5%). Merck answers with revenue growth (9% vs 2.7%).
| Metric | Merck | Bristol Myers Squibb |
|---|---|---|
| Quality score (0-100) | 48 | 77 |
| Net margin | 4.8% | 18.9% |
| Gross margin | — | — |
| ROE | 7.6% | 41.6% |
| Net debt/EBITDA | 4.32× | 2.03× |
| FCF margin | 24.1% | 23.3% |
| Revenue growth (annualized) | 9% | 2.7% |
| Earnings growth (annualized) | -13.5% | 8.7% |
TTM metrics with official SEC data, refreshed daily. Bold green marks the winner of each metric. A dash means the metric doesn't apply or isn't reliable.
Merck. Merck is one of the world's largest pharmaceutical companies. Its business depends largely on a blockbuster cancer drug (Keytruda), plus vaccines and animal health.
Bristol Myers Squibb. Bristol Myers Squibb is a big pharma focused on oncology, hematology and immunology. It's living the sector's classic transition: its legacy blockbusters are losing patent protection and must be replaced by a new generation of drugs bought and developed at great expense.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
What this comparison doesn't tell you
The score measures business quality, not whether the stock is cheap or expensive: the better company can be the worse investment if you overpay. For the valuation verdict, enter each one's current price in the analyzer:
Who has the stronger fundamentals today, Merck or Bristol Myers Squibb?
By the StockSemáforo model (profitability, growth and financial strength, built on official SEC data), Bristol Myers Squibb scores higher: 77 versus 48 out of 100. The score is recomputed nightly with the latest filings.
Does that make Bristol Myers Squibb the better investment?
No. The score measures business quality, not valuation: an excellent company can trade at an excessive price and be a poor investment at that price. To find out whether it's cheap or expensive, enter its current quote in the StockSemáforo analyzer.
Other comparisons
Pfizer vs Merck · Johnson & Johnson vs Pfizer · Eli Lilly vs AbbVie · Amgen vs Gilead · UnitedHealth vs CVS Health · See all comparisons →
Who's behind the methodology and model · how the score is computed
Data: official SEC filings (EDGAR) · Recomputed on September 11, 2026
Spotted a figure that looks wrong? Report it and we'll review it.